Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05. Progression-free survival data was immature, but trending in favor of pirtobrutinib. BRUIN CLL-314 is the first-ever head-to-head Read More